|
Post by sportsrancho on Feb 1, 2017 20:56:42 GMT -5
i do like that Matt said we are doing this possible R/S out of strenght not weakness like some Companies. And you believe that? They both sounded like death warmed over:-(
|
|
|
Post by mnholdem on Feb 1, 2017 21:04:26 GMT -5
The statement is not so hysterical, IMO. We're not some biotech company who must do a R/S because our drug candidate failed to meet its endpoints in a clinical trial. MannKind does have an excellent, potentially market-disruptive insulin and have just replaced the temporary/contract sales reps with a significantly larger and better sales force armed with two new titration packs designed to make prescribing easier for physicians and titrating less cumbersome for the patient and motivated by a stock option plan that will reward performance.
The "position of strength" Matt is referring to is valid. MannKind has Afrezza. MannKind has made the deals so that 70% of patients with diabetes can get coverage for Afrezza. MannKind has hired and expanded sales force and significantly enlarged the nurse educator force (per diem vs fixed) and, finally, MannKind has enough cash to launch focused regional DTC advertising of Afrezza.
There are numerous biotech companies in much, much worse shape than this.
|
|
|
Post by madog365 on Feb 1, 2017 21:18:13 GMT -5
I apologize as I did not read all of the posts threads since 5 pm and could be repeating something.
Is a 180 dayextension still a possibility? Could it be possible to have the vote for R/S lined up with an intention to get it approved for only in case the extension is not granted (a backup plan). If it is granted could the vote be cancelled?
Just some questions , I am not sure maybe someone else knows.
|
|
|
Post by oldfishtowner on Feb 1, 2017 21:21:04 GMT -5
I have spoken to one of the regional managers recently and I can tell you he is extremely enthusiastic about the future of Afrezza, MannKind and Michael. Is he biased? Of course he is but the tone in his voice sounded sincere. Additionally, tone of voice might be something where one's own bias might influence perception. Would be much better if there were some concrete information indicating a meaningful change in script trajectory is coming. As much was said as could have been regarding script trajectory. My take on what has been going on is that with the transition in the sales force, for all intents and purposes, little has been happening in the field for several weeks and the new MNKD sales force won't be in the field for another 2 weeks. What did you expect Mike to say about scripts? He did touch on three important points that will impact scripts, and are the only developments that provide any hope that scripts will iprove significantly over the next 3 months and provide some support for the stock price. These are: 1) 70% of lives covered, most without PA, in the commercial sector. Compared with the state of affairs at the end of 2016, this is huge. 2) The MNKD sales force is double the size of the contract team, is of better quality and well motivated. This is also positive. 3) the new sample packs are available (though there is some question as to whether they have been getting to physicians offices from Mike's comments) and they and the titration packs will be distributed to physicians by the new sales team beginning the middle of the month. The unknown here is whether these will have the impact on patient experience and solving the dosing issue that Mike hopes they will have. It will take a couple of quarters to see whether the new sample packs and the flex packs have the desired effect. While the improvement in insurance coverage and the doubling of the sales force would lead one to believe that script growth should improve in the next few months over what is was last year, and possibly even surpass what Sanofi was able to achieve, it would have been foolish of Mike or Matt to have made specific predictions. What is needed, as others have said, are results. Results speak for themselves. However, whether the results will be sufficient or in time to avoid significant dilution is anyone's guess.
|
|
|
Post by sportsrancho on Feb 1, 2017 21:21:45 GMT -5
Not a fair assessment silentknight. After a 10:1 split, the price fluctuations in the share price should be on the order of 10 times the fluctuations pre-split. Great point. Thanks for that!
|
|
|
Post by rockstarrick on Feb 1, 2017 21:24:16 GMT -5
I apologize as I did not read all of the posts threads since 5 pm and could be repeating something. Is a 180 dayextension still a possibility? Could it be possible to have the vote for R/S lined up with an intention to get it approved for only in case the extension is not granted (a backup plan). If it is granted could the vote be cancelled? Just some questions , I am not sure maybe someone else knows. I believe a RS is required to qualify for the extension ?? does anybody know if this is true.
|
|
|
Post by wildthing on Feb 1, 2017 21:26:39 GMT -5
The statement is not so hysterical, IMO. We're not some biotech company who must do a R/S because our drug candidate failed to meet its endpoints in a clinical trial. MannKind does have an excellent, potentially market-disruptive insulin and have just replaced the temporary/contract sales reps with a significantly larger and better sales force armed with two new titration packs designed to make prescribing easier for physicians and titrating less cumbersome for the patient and motivated by a stock option plan that will reward performance.
The "position of strength" Matt is referring to is valid. MannKind has Afrezza. MannKind has made the deals so that 70% of patients with diabetes can get coverage for Afrezza. MannKind has hired and expanded sales force and significantly enlarged the nurse educator force (per diem vs fixed) and, finally, MannKind has enough cash to launch focused regional DTC advertising of Afrezza.
There are numerous biotech companies in much, much worse shape than this. MNKD is going up against three very wealthy and deeply entrenched big pharmas. Any military type would tell you it requires a 3 to 1 ratio of firepower to even consider attacking such a defensive position. Until MNKD offers up a clinical trial proving that afrezza produces significant clinical benefits to its regular prandial users superior to those offered by humalog/novoloh/apidra, they're going to be attacking armed with little more than a water gun. Alternatively, perhaps they could find a way to partner with Lilly or Novolog.
|
|
|
Post by gamblerjag on Feb 1, 2017 21:29:37 GMT -5
They did sound terrible but that could be just because they didn't want to deliver the call.. Sports you know I'm always 1/2 full.. to a fault... but i figure i'm not going to get upset until I know what does happen.. and a r/s if that happens isn't always bad. as I said I had a company that was 5 cents did a 50-1 r/s to 2.50... back in 2002... it dropped over the next few months to around .60 cents then over the next 18 months hit 27 bucks and stayed in the 20's for a couple of years... cont good luck.
|
|
|
Post by gamblerjag on Feb 1, 2017 21:31:21 GMT -5
I do... good luck.. there are things i don't believe... i didn't believe AMGN was going to be discussed today..
|
|
|
Post by kc on Feb 1, 2017 21:32:51 GMT -5
There is less than 17% held by institutions. It's the hedges that control Mannkind. My appology: I tend to summarize this under "institutions". Or do you believe that these are some retail lone wolves? Nope they're definitely hedge fund shorts are just sitting there grinding. Perhaps naked shorts. I think that's one of the reasons why a reverse split will solve some of that problem. This shares have to be accounted for in the vote.
|
|
|
Post by sportsrancho on Feb 1, 2017 21:40:19 GMT -5
They did sound terrible but that could be just because they didn't want to deliver the call.. Sports you know I'm always 1/2 full.. to a fault... but i figure i'm not going to get upset until I know what does happen.. and a r/s if that happens isn't always bad. as I said I had a company that was 5 cents did a 50-1 r/s to 2.50... back in 2002... it dropped over the next few months to around .60 cents then over the next 18 months hit 27 bucks and stayed in the 20's for a couple of years... cont good luck. Time is money. It just gets old to have to keep starting over. That being said, I do believe that could happen to us also. I'd rather hang with the glass half full gang:-). Let's get this done and sell Afrezza! I really believe it's more like one out of a 1,000 that does not know about it YET!
|
|
|
Post by madog365 on Feb 1, 2017 21:40:23 GMT -5
I apologize as I did not read all of the posts threads since 5 pm and could be repeating something. Is a 180 dayextension still a possibility? Could it be possible to have the vote for R/S lined up with an intention to get it approved for only in case the extension is not granted (a backup plan). If it is granted could the vote be cancelled? Just some questions , I am not sure maybe someone else knows. I believe a RS is required to qualify for the extension ?? does anybody know if this is true. You're right I looked it up on nasdaq website , a short term plan wth an approved r/s is required to qualify. See language below. Nasdaq FAQ What happens if a company does not regain compliance with the minimum bid price requirement during the compliance period? If a company is unable to resolve its bid price deficiency during the applicable compliance period, Nasdaq Staff will issue a delisting letter. At that time, the company may request a hearing before a Hearing Panel, which will stay the delisting. The company will have the opportunity to present its plan to regain compliance to the Panel. This plan of compliance should include implementation of a reverse stock split in the near term. In appropriate cases, and so long as a company commits to implementation of a reverse split within 180 days of the delisting notification, Panels may also consider other factors, such as the company's fundamental financial strengths and weaknesses, the overall market, the company's historical bid price, and impending disclosures, corporate actions and strategic business plans that the company believes may impact its bid price.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 1, 2017 21:41:18 GMT -5
That was a really sad call. Sad, as in, like losing a family member. I am sorry for all of you that have lost money. This community of share holders is really a cult. One that I wouldn't say I was apart of, but one that influenced my decisions (and that is my own fault) but it taught me a lot. Even now in this thread some still refuse to face the music. MNKD has brought many share holders together through different social media avenues. It gave a lot of people a daily purpose. How many share holders have gone through this day?
Get up every morning read proboards, read yahoo, read seeking alpha, stocks down 20% god damn those shorts and their dark pools, script numbers suck again, oh its a controlled launch by sanofi, Adam Feurstein is the devil, Nates news letters is finally here and if he is so good maybe Im not making the wrong decision he wont lead me down the wrong path, shorts are destroying the company, good news is coming next conference call, volkswagon squeeze is coming its coming etc etc etc etc and the reality is LONGS ARE TOO STUBBORN TO ADMIT THEY MADE A BAD BET.
When I was in the thick of this investment MNKD became apart of my routine and life. A nightmare groundhog day in which everyday my assets went down even more. Its quite embarassing but I dont blame anyone for getting sucked in. Those damn user reviews......those damn user reviews.....
|
|
|
Post by afrizzle on Feb 1, 2017 21:59:14 GMT -5
Why no Q&A at the end?
|
|
|
Post by sweedee79 on Feb 1, 2017 22:03:31 GMT -5
Probably because in a situation like this the less you say the better off you are.. cuz the market is listening to every word
|
|